Once you review this piece, consider buying or watch listing this unique biopharmaceutical company. The company’s focus is therapy and, eventually, possibly, a cure for Pancreatic Cancer, arguably the deadliest form.
RenovoRx (Nasdaq: RNXT) is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform. Oncology is an international peer-reviewed journal for practicing oncologists and hematologists.
Over and above a great chart, there are salient points to consider.
- Currently, at USD1.25, several analysts have projected the share to move to USD8.00 on the high end and USD4.00 at the low.
- Recent robust trading volumes
- Presentations at many high-level Biotech conferences;
- Ongoing Phase III TIGeR-PaC cRNXT’Sl trial RNXT’S ON TAMP therapy platform (Trans-Arterial Micro-Perfusion) therapy platform for treating Locally Advanced Pancreatic Cancer (LAPC.)
- Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment ofRenovoRx on RenovoRx’s pivotal ongoing Phase III TIGeR-PaC clinical trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC.)
- Attainment of Orphan Drug status—this is key.
Status is given to certain drugs called orphan drugs, therapies which show promise in the treatment, prevention, or diagnosis of orphan diseases. An orphan disease is a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan diseases are often severe or life-threatening. Also, Orphan Drug status is given to those few companies that develop products that address the public good and not simply for profit.
Behind all this, biotech is an excellent therapy with the potential to lower deadly numbers of Pancreatic Cancer. Targeting Pancreatic Cancer, which has a 5-year survival rate that is 3% (and that’s stage 1-4). That is 18 percent of patients a year. Moreover, 13% will not survive past five tears. As we all know, Pancreatic cancer is a nasty disease. RNXT’s work has the benefit of addressing this most heinous form of cancer.
Have a look at RenovoRx, as the parts really do add up to decent growth in your portfolio.
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
